Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer

Conclusion: Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency.

Source: In Vivo - November 3, 2020 Category: Research Authors: CHIKAZAWA, K., IMAI, K., ITO, T., KIMURA, A., HIROYOSHI, K., MIHO, Y., KUWATA, T., KONNO, R. Tags: Clinical Studies Source Type: research